Application of ɑ-Tocotrienol-Loaded Biocompatible Precirol in Attenuation of Doxorubicin Dose-Dependent Behavior in HUH-7 Hepatocarcinoma Cell Line

Nutrition and Cancer
Ailar TupalFatemeh Ramezani

Abstract

Tumor-targeted nanoparticle delivery system has been known as a substitute and capable achievement in cancer treatment compared to conventional methods. In this study, we examined potential application of ɑ-tocotrienol-Precirol formulation to enhance efficiency of doxorubicin (DOX) in induction of apoptosis in HUH-7 hepatocarcinoma cells. ɑ-tocotrienol-loaded nanoparticles were characterized at the point of zeta potential, particle size, scanning electron microscope (SEM), and cell internalization. To evaluate antiproliferative effects of formulation, apoptosis, cell cycle procedure, flow cytometry, and MTT assays were employed. Optimum size of the ɑ-tocotrienol formulation revealed narrow size distribution with mean average of 78 ± 3 nm. IC50 values for ɑ-tocotrienol and ɑ-tocotrienol-nano structured lipid carriers after 24 h were 15 ± 0.6 and 10 ± 0.03 µM, respectively. After incubation of cells with ɑ-tocotrienol-loaded careers, the rate of cell proliferation decreased from 53 ± 6.1 to 34 ± 7.1% (P < 0.05). A significant improvement in the apoptosis percentage was revealed after treatment of the HUH-7 cell line with DOX and ɑ-tocotrienol careers (P < 0.05). Gene expression results demonstrated a marked decrease in survivin a...Continue Reading

References

Oct 2, 1992·Journal of Medicinal Chemistry·B C PearceJ J Wright
May 13, 2005·Journal of Ethnopharmacology·C C Lee, Peter Houghton
Jun 10, 2006·Biochemical and Biophysical Research Communications·Janmejai K Srivastava, Sanjay Gupta
Sep 1, 2006·Journal of the American College of Nutrition·Marion DietrichGladys Block
Mar 30, 2007·Lipids·Wakako TsuzukiHiroyuki Yoshimura
Nov 29, 2007·Biochemical and Biophysical Research Communications·Korehito KashiwagiTomohiro Yano
Jun 6, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Surajit DasReginald B H Tan
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Dec 2, 2014·Nutrition & Metabolism·Haseeb AhsanWaseem A Siddiqui
Dec 3, 2014·International Journal of Pharmaceutics·Antonio LeonardiRosario Pignatello
Dec 7, 2014·BMC Complementary and Alternative Medicine·Su-Wen LimNazariah A Zeenathul
Dec 15, 2015·Nanomedicine·Vahid Heravi SharghMingtao Liang
Dec 27, 2015·Pharmacology & Therapeutics·Hong Yong PehW S Fred Wong
Jan 11, 2016·Molecular Biology Reports·Akbar MinaeiNasser Samadi
Mar 8, 2016·BioFactors·Leanne De SilvaJu-Yen Fu
Aug 10, 2017·Drug Discovery Today·Madhu M KanchiAlan P Kumar
Jan 10, 2018·Artificial Cells, Nanomedicine, and Biotechnology·Hamed HajipourRamezan Ali Taheri

❮ Previous
Next ❯

Citations

Feb 6, 2021·Hormone Molecular Biology and Clinical Investigation·Pirouz PourmohammadYavar Mahmoodzadeh
Jan 23, 2020·Hormone Molecular Biology and Clinical Investigation·Vahid VahedianNazila Fathi Maroufi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
flow cytometry

Software Mentioned

Cell QuestTM

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Related Papers

Revista clínica española
B Sangro Gómez-Acebo, J Prieto Valtueña
Gastroenterología y hepatología
B Sangro Gómez-Acebo
Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva
F J Martínez CerezoJ Enríquez
Gastroenterología y hepatología
M H Núñez RodríguezA Caro-Patón Gómez
© 2021 Meta ULC. All rights reserved